• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Rethinking orthopedic implants with Arthrosurface CEO Steve Ek | DeviceTalks Podcast

Rethinking orthopedic implants with Arthrosurface CEO Steve Ek | DeviceTalks Podcast

June 24, 2019 By Sarah Faulkner

Arthrosurface president & CEO Steve Ek talked to reporter Sarah Faulkner about the company’s motion-preserving joint replacement technology. Want to see these interviews live? Join us at DeviceTalks. 

Sarah: Steve’s office is not your typical corporate office. It’s filled with models of the human skeletal system and demos of the company’s implants. It’s a good representation of Steve’s career in medtech, since he’s spent nearly 30 years building and selling orthopedic devices and implants.

Sarah: Steve is president & CEO of Arthrosurface and he’s also one of the company’s founders. He told me that the inspiration for the company’s technology came from talking to surgeons and learning that there was a group of patients that these surgeons just weren’t sure how to treat.

Steve: I saw, and a lot of surgeons saw this too, that when a patient is a certain age, they go from tearing their meniscus or tearing their ACL and needing a slight rotator cuff repair or whatever, then as you age on, some of that damage you did starts to turn into joint disease. And a lot of those injuries in fact trigger the start of those pathologies and time goes by, twenty years later and those patients now need more intervention.

Steve: So they sort of age out of the sports medicine world, and start entering into the total joint world. But now, with the activity levels of people and what-not, that’s a big bracket. So that people who are aging out, so that they can no longer really get a benefit from arthroscopic procedure but they’re arguably too young for total joint, they can get stuck in the middle and when we started this company, a lot of surgeons would say ‘Well, you’re too young for total joint so change your lifestyle, stop doing those activities, and come to me when you’re 55, 60.’ And we saw that so much, that we said, you know there’s a real opportunity here for the orthopedic tweeners if you will, and that’s when we started this company.

Steve: There was a moment where a founding surgeon, Tony Miniaci – who is now at the Cleveland Clinic but at the time practiced in Canada – I went to a closed meeting with him, where there were a number of surgeons presenting their patients that they couldn’t do anything else with and about six guys got up and showed individual cases of patients they had no idea how to treat and they were all joint defects where there was a loss of cartilage and they were symptomatic. So they were feeling the same pain you feel that drives you in to get a total knee or a total hip. They were feeling but the amount of damage was much earlier on. So, say you’re missing something besides a quarter on a joint surface, every time you take a step, you still feel that pain. But the joint, for the most part was still intact in these people, but they had a localized area that was gone. And all of them were basically disabled, if you will, or had to give up all of their activities because they were all symptomatic.

Steve: So we said, well why don’t we take the concept of doing a joint replacement but do a very small version of it and just replace this damaged area.

Sarah: It took four years for the company to complete its preclinical work and bring its first implants into human beings. Since then, Steve and his team have learned a lot about what it means to build a functioning implant.

Steve: What we learned was you have to develop an implant that will try to pass the loads through to the joint, in as close to a normal way as possible.

Steve: So then we looked at what have total joints done and a lot of them didn’t do that. A lot of joints, there’s a boney portion and most long bones in our body are hollow and so a lot of traditional joints would just stick a stem into these hollow spots, cut everything else off and rely on that sort of press-fit fixation into the stem or cement and expect that to try and last some amount of time.

Sarah: As it turns out, that’s not really the way our body works. That process doesn’t authentically replicate the load that the joints take on. So Arthrosurface tried something different, according to Steve.

Steve: So what we try to do is A: keep the implant as small as we could, keep the implants as thin as we could, and try to design the implant so it passes most of that load through in a normal, anatomic way. And so when you look at all of our implants, they all have a sort of similar attributes.

Steve: We have very thin implants, as thin as you can get them. And when you compare that to traditional joint replacements, they’re very different. So very thin implants so that some of the loads pass through. And then all of our implants also have this sort of, concept where we put a fixation element into the bone, it’s a tapered screw. It’s tapered so that each ring of the threading won’t shield the more proximal or more distal thread from the loads, and that thread and screw pass the loads into this, what’s called a subchondral bone. So all we’re trying to do is, if I put a load here, in engineering terms, you’ll see sort of a triangle of loads that form into the bone.

Steve: We just wanted to replicate that. Try to get the loads to go into the bone. There’s Wolf’s Law, in orthopedics. If you un-stress a bone, or change its stress, it will react. So people that have, that are involved in a lot of activities and exercise, their bone density increases. Because the body says, I need to thicken up this bone to make it stronger. People that don’t have thinner, less dense bones. If you shield a bone from a load, the body will resorb it. So that’s what we took, to have an implant that goes into a young patient and has to survive a long time, we have to maintain the bone around it, not just design the implant to last five million cycles, we have to design the system so it still passes the loads into the bone and preserves the bone.

Steve: We have to really recreate the existing geometry or else it will be a disaster, right? So, we learned how to do that fairly early on.

Sarah: The company has a number of implants in its portfolio, including ones for the shoulder, wrist, knee, foot and ankle. To figure out where the company should create new products, Steve told me they talk to doctors to find out where the most need lies.

Steve: There are a lot of operations and orthopedics where the procedure is designed to eliminate pain, but at great compromise to the function. And so when we see procedures like that, we’re like, okay, we got this, this is our sweet spot.

Sarah: Arthrosurface also determines new potential clinical areas for their products by learning that doctors are using existing products off-label. For the company’s wrist implant, for example, they learned that surgeons were using Arthrosurface’s toe product off-label in the wrist.

Sarah: And then, of course, there’s the question of how long the implants can last. Steve told me that when the company first launched, they conservatively told surgeons that the implants would last five years.

Steve: So when we first launched we were very conservative and said, this is an interim treatment it will buy you five years to continue your activities and then the other part of this is, we design all of our systems so that if the patient goes on to need a traditional joint replacement, you take our hardware out and it’s like they’re going in for a procedure like we were never there.

Sarah: But now, the company feels comfortable telling patients that they could get nearly a decade of use from their implants. And even more interestingly, Arthrosurface is exploring whether or not their implants could stop the progression of arthritis altogether.

Steve: We had two cohorts of patients with treatment group A and our treatment group, and we saw that at two years, with our implant in, we actually quiet the joint down. So you are halting some of those degenerative changes. So to me that’s one of our boldest claims we’ve made as a company. Imagine that if you, the historic thinking is, you just have to ride it out and then get a total joint. That paper to me, makes you challenge that and say, no you want to treat it and halt it, and you might be able to stop the progression. It’s a singular paper right now. But it’s, I think it’s something that can be, it will paradigm shift the thinking clinically over time if that continues to be born out.

Steve: I realize now, I had a rotator cuff repair a few years ago, and so you spend, you know, six-months regaining function of your shoulder. And I got a real appreciation for how frustrating it is, I mean you adapt because we’re humans and that’s what we do, and we’re realists, so we say, okay I don’t have my shoulder, so I’ll just figure out some other way to do it. But you learn that, wow my legs and hips get me there, but my shoulder allows me to do most everything else. And you start looking at things you are incapable of doing and you realize, you understand what the different parts of our body, it gives you kind of an evolutionary appreciation.

Steve: Okay first I have to ambulate to get there, then I have shoulders and hands and elbows to do the fine motor skills. Like you start realizing, okay I can do some things, but I can’t do other things, and it’s, I don’t know. We should all have to do six-weeks in a sling just to get a better appreciation.

Sarah: Steve also pointed out that the need for the company’s technology is really rooted in an aging population.

Steve: People born today, their life expectancy is somewhere around 120 years. The diseases that we are targeting start showing up in your forties. In the evolution of traditional orthopedics, you are getting an implant at 65 and presumably you are checking out 75, 80. So you have to really rethink the whole thing. You can’t just assume there’s gonna be a single intervention. There probably has to be multiple interventions along the way. So, I think we’re in a great spot where we are. And we’ll have to continue to watch.

Interested in live interviews with key medtech leaders? Join us at DeviceTalks.

Filed Under: Device Talks Podcasts, Featured, Orthopedics Tagged With: Arthrosurface, DeviceTalks

In case you missed it

  • Orchestra BioMed to go public, partner with Medtronic on cardiac neuromodulation therapy
  • Memic Innovative Surgery is now Momentis Surgical
  • Lyra Therapeutics appoints new chief medical officer
  • Masimo’s SafetyNet monitoring reduced length of COVID-19 hospital stays, study says
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

RSS From Medical Design & Outsourcing

  • DeviceTalks Boston 2022: Here’s what you missed on the show floor
    At DeviceTalks Boston 2022, there was a wealth of expertise to be had from exhibitors including Viant, ICS, PSN Labs, Propel and more. From stories of overcoming challenges during the COVID-19 pandemic to medical device materials pitfalls to avoid, MassDevice and MDO executive editor Chris Newmarker hit the DeviceTalks Boston show floor to discover insights. […]
  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS